PedAM
Pediatric Disease Annotations & Medicines
| Disease | hepatocellular carcinoma |
| Phenotype | |cirrhosis |
| Sentences | 171 |
| PubMedID- 23118578 | The transcatheter arterial chemoembolization (tace) method has been widely used for the management of unresectable, advanced hepatocellular carcinoma (hcc) in patients with compensated liver cirrhosis (1). |
| PubMedID- 22028976 | In hepatocellular carcinoma, all patients with liver cirrhosis or chronic hepatitis b virus infection are at risk. |
| PubMedID- 21462175 | Resection of hepatocellular carcinoma in patients without cirrhosis (br j surg 2011; 98: 697-703). |
| PubMedID- 23607898 | Aim: hepatectomy for hepatocellular carcinoma (hcc) in patients with primary biliary cirrhosis (pbc) has seldom been reported, and the clinical significance of this procedure remains unclear, although hcc has often been observed in end-stage pbc patients. |
| PubMedID- 23874878 | Hepatic steatosis can progress to non-alcoholic steatohepatitis (nash), cirrhosis and development of hepatocellular carcinoma. |
| PubMedID- 24202543 | 2009) and even higher among patients suffering from cryptogenic hepatitis or cryptogenic cirrhosis with hepatocellular carcinoma (10–74 %); (bokharaei-salim et al. |
| PubMedID- 23775581 | From the baseline lic and serum ferritin reported [9], it is clear that despite no/limited transfusions, these patients have high iron burden, and this high burden has been associated with complications such as bone disease, thromboembolism, endocrinopathy, pulmonary hypertension, cerebrovascular and neuronal damage, liver fibrosis or cirrhosis, and increased risk of hepatocellular carcinoma (for overview see [16]). |
| PubMedID- 26469163 | Methods: thirty consecutive cases of percutaneous arterial chemoembolization for hepatocellular carcinoma with hepatitis c-related cirrhosis(male, 23; female, 7; age, 74+/-5.9; weight, 62.7+/-12.3 kg; child-pugh a, 23; child-pugh b, 7)were analyzed retrospectively. |
| PubMedID- 22208688 | Objective: liver transplantation (lt) is known to be a promising treatment for patients with liver cirrhosis associated with hepatocellular carcinoma (hcc). |
| PubMedID- 22570565 | Transarterial chemoembolization (tace) is an established local therapy for managing unresectable hepatocellular carcinoma (hcc) in patients with advanced cirrhosis and confers significant survival benefits.1,2 iodized oil is usually used as a carrier of most anticancer agents to achieve preferential uptake and persistent deposit of the chemotherapeutic agent within the hcc nodules in conventional tace. |
| PubMedID- 26155045 | hepatocellular carcinoma without cirrhosis presenting with hypercalcemia: case report and literature review. |
| PubMedID- 22606287 | Ald-associated disorders include fatty liver, inflammation, and hepatocellular carcinoma in patients with liver cirrhosis [41]. |
| PubMedID- 21527064 | Since 85% of hepatocellular carcinoma (hcc) develops in patients with cirrhosis of the liver and its associated liver insufficiency, it is essential the hcc therapy spares uninvolved liver to minimize the risk of further compromise of hepatic function [54]. |
| PubMedID- 20425481 | Progressive hepatic fibrosis is the final common pathway for most chronic liver injuries, leading to cirrhosis with risk of liver failure and hepatocellular carcinoma. |
| PubMedID- 26444667 | Negative impact of low body mass index on liver cirrhosis patients with hepatocellular carcinoma. |
| PubMedID- 23113141 | Self-limited acute or fulminant hepatitis, asymptomatic infection, or chronic hepatitis with progression to liver cirrhosis that can lead to hepatocellular carcinoma (10). |
| PubMedID- 19345541 | Percutaneous laser ablation of hepatocellular carcinoma in patients with liver cirrhosis awaiting liver transplantation. |
| PubMedID- 22869451 | In this issue of the journal (beginning on page 1007), nkontchou and colleagues report their retrospective observational finding that the beta-blocker propranolol was associated with a highly statistically significant reduction in the incidence of hepatocellular carcinoma in patients with advanced cirrhosis and related esophageal varices. |
| PubMedID- 21176666 | [peri-operative treatment for hepatocellular carcinoma patients complied with cirrhosis and hypersplenism]. |
| PubMedID- 25339803 | Some of these people will develop hepatic cirrhosis with decompensation and/or hepatocellular carcinoma. |
| PubMedID- 24040153 | Human hcv infection causes chronic liver disease, cirrhosis, and is associated with hepatocellular carcinoma [2]. |
| PubMedID- 22038662 | Results: fifteen hepatocellular carcinoma patients with child-pugh a cirrhosis, in whom sorafenib dosing remained unchanged from initiation of treatment to disease progression, were eligible for this analysis. |
| PubMedID- 20487573 | Serum egf levels were 1.8-fold higher in g/g hepatocellular carcinoma patients with cirrhosis than a/a patients, and liver egf levels were 2.4-fold higher in g/g patients than a/a patients. |
| PubMedID- 21302626 | Effective and safe systemic treatment for advanced hepatocellular carcinoma (hcc) with severe underlying cirrhosis is not yet available. |
| PubMedID- 23126044 | hepatocellular carcinoma mostly develops in patients with liver cirrhosis due to chronic hepatitis c virus (hcv) infection. |
| PubMedID- 23696887 | cirrhosis precedes most cases of hepatocellular carcinoma (hcc), with 70%–90% of hcc developing from a background of chronic liver cirrhosis [4]. |
| PubMedID- 24707433 | A 68-year-old man underwent a first cadaveric orthotopic liver transplantation for hepatitis b virus and alcohol-induced cirrhosis that was complicated by hepatocellular carcinoma. |
| PubMedID- 21663667 | About 75% of patients achieve no therapeutic benefit from the present combination therapy with pegylated interferon α (peg-ifn-α) and ribavirin mainly depending upon hcv genotype, whereas in 40-60% patients chronic infection is mainly associated with liver cirrhosis and steatosis leading to hepatocellular carcinoma (hcc) [3-5]. |
| PubMedID- 26155261 | Backgrounds/aims: the prognosis of hepatic resection for hepatocellular carcinoma (hcc) in patients with cirrhosis is worse than in those without cirrhosis. |
| PubMedID- 25212123 | Whether preoperative clinically significant portal hypertension (csph) has or not an impact on the outcome of surgery for hepatocellular carcinoma (hcc) in patients with compensated cirrhosis is debated. |
| PubMedID- 20517476 | Hepatitis c virus (hcv) is a major human health problem worldwide which can result in acute and chronic hepatitis, cirrhosis, and/or development of hepatocellular carcinoma. |
| PubMedID- 22504244 | We describe a well-differentiated hepatocellular carcinoma (hcc) with alcohol-related liver cirrhosis in a 69-year-old man. |
| PubMedID- 21357524 | Purpose: to investigate the usefulness of computed tomographic (ct) spectral imaging parameters in differentiating small (hepatocellular carcinoma (hcc), with or without cirrhosis, during the late arterial phase (ap) and portal venous phase (pvp). |
| PubMedID- 23904843 | The greatest advantage of pure laparoscopic hepatectomy for hepatocellular carcinoma with concomitant liver cirrhosis is that postoperative ascites retention is minimal, meaning that there is little risk of water-electrolyte imbalance associated with ascites retention or hypoproteinemia. |
| PubMedID- 21682829 | Furthermore, clinical trials have shown that sho-saiko-to lowers the rate of hepatocellular carcinoma (hcc) development in patients with cirrhosis and increases the survival of patients with hcc. |
| PubMedID- 23691139 | This appears to happen during hepatocellular carcinoma (hcc) development in patients with liver cirrhosis, however, the accompanying transcriptional changes are virtually unknown. |
| PubMedID- 25138286 | Purpose: the aim of this retrospective cohort study was to clarify the effect of a branched-chain amino acids (bcaa) on the liver function and the prognosis of child-pugh class (c-p) a and b liver cirrhosis (lc) patients with advanced hepatocellular carcinoma (ahcc) undergoing hepatic arterial infusion chemotherapy (haic). |
| PubMedID- 23894275 | Nonalcoholic steatohepatitis (nash) often leads to cirrhosis and development of hepatocellular carcinoma. |
| PubMedID- 25751727 | Nash may progresss to fibrosis or cirrhosis [5], leading to hepatocellular carcinoma (hcc) [6] and even liver-related mortality [7]. |
| PubMedID- 23316254 | Demonstrate that sorafenib-induced th1 dominance can prevent the escape of tumor cells from the host immune system in liver cirrhosis (lc) patients with advanced hepatocellular carcinoma (ahcc). |
| PubMedID- 22941170 | Background: initial therapy for early hepatocellular carcinoma (hcc) with well-compensated cirrhosis is controversial. |
| PubMedID- 22523693 | These pleiotropic and highly variable functions go some way towards explaining the miscellany of associations that have been detected for vdr polymorphisms, among others with the occurrence of hepatocellular carcinoma (hcc) in patients with liver cirrhosis, particularly in patients with an alcoholic etiology [30]. |
| PubMedID- 25427740 | Background: in most guidelines, no other interventional therapy but liver transplantation is recommended for the treatment of hepatocellular carcinoma (hcc) with child-pugh c cirrhosis (cp-c). |
| PubMedID- 22013259 | The first patient was a 45-year-old male hepatitis c related cirrhosis with hepatocellular carcinoma, child grade c, with refractory ascites, coagulopathy and mild hepatorenal syndrome. |
| PubMedID- 23780836 | Conclusion: serum endocan and syndecan-1 are easily assessable prognostic serum biomarkers of overall survival in alcoholic cirrhosis with and without hepatocellular carcinoma. |
| PubMedID- 23958083 | Background & aims: liver transplantation (lt) is a promising treatment for patients with liver cirrhosis associated with hepatocellular carcinoma (hcc). |
| PubMedID- 24420645 | Improving survival of cirrhosis patients with hepatocellular carcinoma through application of standard of care. |
| PubMedID- 21457561 | An estimated 3% of the world's population is chronically infected with hepatitis c virus (hcv) which is the main cause of liver fibrosis and cirrhosis, often leading to hcc (hepatocellular carcinoma) in a substantial number of patients. |
| PubMedID- 25963079 | Methods: using seldi-tof ms, serum protein/peptide profiles on the cm10 proteinchip arrays were obtained from a training group including 26 hbv-associated hepatocellular carcinoma patients with liver cirrhosis (lc), 30 hbv-associated lc patients, 85 patients at different stages of liver fibrosis, and 30 asymptomatic hbv carriers. |
| PubMedID- 22882828 | Characterizing the metabolic changes pertaining to hepatocellular carcinoma (hcc) in patients with liver cirrhosis is believed to contribute towards early detection, treatment, and understanding of the molecular mechanisms of hcc. |